FCGR2A and neoplasm: Even in complex transgenic mouse models engineered to express all human FcγR on the respective murine effector populations the contribution of the complement system might not be adequately reflected and tumor location and tumor burden may have a significant impact on which effector mechanisms contribute to the therapeutic activity in a given situation [15,53,54].